SRINAGAR: To raise awareness about respiratory health during the winter season, the Health Centre, University of Kashmir (KU), organized a health talk by noted ...
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I'm dealing with the effects of it ...
Itepekimab is under development for the treatment of chronic obstructive pulmonary disease, non-cystic fibrosis bronchiectasis. It is administered intravenously and subcutaneously. The drug candidate ...